Biotech Values

[DewDiligence]

RAIN -87% on phase-3 failure in liposarcoma:

https://finance.yahoo.com/news/rain-oncology-announces-topline-results-120000095.html

Rain Oncology, …a late-stage company developing precision oncology therapeutics with its lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced its topline pivotal Phase 3 MANTRA data.

The trial, evaluating the efficacy, safety, and tolerability of milademetan in patients with dedifferentiated (DD) liposarcoma (LPS), did not meet its primary endpoint of progression free survival (PFS) by blinded independent central review compared to the standard of care, trabectedin [Yondelis].

The HR for PFS was 0.89, p=0.53.